Measuring the economic benefit of treatment with atypical antipsychotics

European Psychiatry

Volumn 13, Issue SUPPL.1, 1998, Pages

  Knapp, M R J ^a,b  

^a LONDON SCHOOL OF ECONOMICS   (United Kingdom)

^b KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

Atypical antipsychotics; Costs; Economic evaluation; Schizophrenia; Society

Indexed keywords

CLOZAPINE; NEUROLEPTIC AGENT; RISPERIDONE;

CONFERENCE PAPER; COST BENEFIT ANALYSIS; ECONOMIC ASPECT; FAMILY; HEALTH CARE COST; HOSPITAL COST; HUMAN; PRIORITY JOURNAL; QUALITY OF LIFE; SCHIZOPHRENIA; SOCIAL ASPECT; SOCIETY;

EID: 0031905471     PISSN: 09249338     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0924-9338(97)89492-8     Document Type: Article

References (33)

1. Alleback P. Schizophrenia: a life-shortening disease. Schiz Bull 1989;15:81-9
2. Amaddeo F, Beecham JK, Bonizzato P, Fenyo A, Knapp MRJ, Tansella M. The use of a case register for evaluating the costs of psychiatric care. Acta Psychiatr Scand, in press.
3. Andrews G, Hall W, Goldstein G et al. The economic costs of schizophrenia: implications for public policy. Arch Gen Psychiatry 1985;42:537-43
4. Audit Commission. Finding a Place. London: HMSO ; 1994
5. Beecham JK, Hallam A, Knapp MRJ, Baines B, Fenyo A., Asbury M. Costing care in the hospital and in the community. 11: Leff J, ed. Community Care: Illusion or Reality? Chichester: Wiley; 1997
6. Bloor K, Freemantle N. Lessons from international experience in controlling pharmaceutical expenditure II: influencing doctors. Br Med J 1996;312:1525
7. Chisholm D, Knapp MRJ, Astin J, Beecham J, Audini B, Lelliott P. The costs of residential care for people with mental health problems in eight services. J M Health 1997
8. Davies LM, Drummond MF. Economics and schizophrenia: the real cost. Br J Psychiatry 1994;165 (suppl 25):18-21
9. Department of Health. Health and Personal Social Services Statistics for England. London: HMSO ; 1994
10. Drummond MF. Cost-of-illness studies: a major headache? Pharmacoeconomics 1992;2:1-4
11. Drummond MF, O'Brien B, Stoddart GL, Torrance GW. Methods for the Economic Evaluation of Health Care Programmes 2nd ed. Oxford: Oxford Medical Publications; 1997
12. Evers SMAA, Ament AJHA. Costs of schizophrenia in the Netherlands, Schizophr Bull 1995;21:141-53
13. Freemantle N, Bloor K. Lessons from international experience in controlling pharmaceutical expenditure I: influencing patients. Br Med J 1996;312:1469-71
14. Hallam A. Costs and outcomes for people with special psychiatric needs. Ment Health Res Rev 1996;3:10
15. Hogman G. Is Cost a Factor? London: National Schizophrenia Fellowship 1996
16. Hyde C, Harrower-Wilson C. Resource consumption in psychiatric intensive care: the cost of aggression. Psychiatr Bull 1995;19:73-6
17. Kavanagh SM Stewart A. Economic evaluations of mental health care: modes and methods. In: Knapp MRJ, ed. The Economic Evaluation of Mental Health Care. Aldershot: Arena, 1995
18. Kavanagh S, Opit L, Knapp MRJ, Beecham J. Schizophrenia: shifting the balance of care. Soc Psychiatr Epidemiol 1995;30:206-12
19. Kerwin RW. An essay on the new antipsychotics. Psychiatr Bull 1996;20:23-9
20. Knapp MRJ. Costs of schizophrenia. Br J Psychiatry 1997;171:509-18
21. Knapp MRJ, Beecham JK, Koutsogeorgopoulou V, Hallam A, Fenyo A, Marks I et al. Service use and costs of home-based versus hospital-based care for people with serious mental illness. Br J Psychiatry 1994;165:195-203
22. Lehman AF, Thompson JW, Dixon LB, Scott JE. Schizophrenia: treatment outcomes research. Schizophr Bull 1995;21:561-6
23. Lieberman JA, Fleischhacker WW, eds. Current Issues in the Development of Atypical Antipsychotic Drugs. Br J Psychiatry 1996;168(supp 29)
24. Macmillan JF, Crow TJ, Johnson AL, Johnstone EC. The Northwick Park study of first episodes of schizophrenia. Ill Short term outcome in trial entrants and trial-eligible patient. Br J Psychiatry 1986;148:128-33
25. National Health Service Executive. Burden of disease. London: NHSE; 1996
26. Netten A, Dennett J. Unit Costs of Health and Social Care 1996. Canterbury: Personal Social Services Research Unit, University of Kent at Canterbury ; 1996
27. Rice DP, Kelman S, Miller LS et al. The Economic Costs of Alcohol and Drug Abuse and Mental Illness: 1985. Rockville: National Institute of Mental Health DHSS Pub No (ADM) 90-1694 ; 1990
28. Ritchie JH, Dick D. Lingham R. The Report of the Inquiry into the Care and Treatment of Christopher Clunis. London: HMSO ; 1994
29. Schene AH, Tessler RC Gamache GM. Instruments measuring family or caregiver burden in severe mental illness. Soc Psychiatry Psychiatr Epidemiol 1994;28:11-6
30. Sheldon T. Problems of using modelling in the economic evaluation of health care. Health Econ 1996;5:1-12
31. Shepherd M, Watt D, Falloon I et al. The natural history of schizophrenia: a five-year follow-up study of outcome and prediction in a representative sample of schizophrenics. Psych Med 1989;15:1-44
32. Szmukler G. From family burden to caregiving. Psychiatr Bull 1996;20:449-51
33. Weiden PJ Olfson M. Cost of relapse in schizophrenia. Schizophr Bull 1995;21:419-29